Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Multiple Endocrine Neoplasia Type 2B Presents Early in Childhood but Often Is Undiagnosed for Years.

Makri A, Akshintala S, Derse-Anthony C, Widemann B, Stratakis CA, Glod J, Lodish M.

J Pediatr. 2018 Oct 9. pii: S0022-3476(18)31147-8. doi: 10.1016/j.jpeds.2018.08.022. [Epub ahead of print]

PMID:
30314660
2.

Pheochromocytoma in children and adolescents with multiple endocrine neoplasia type 2B.

Makri A, Akshintala S, Derse-Anthony C, Del Rivero J, Widemann B, Stratakis CA, Glod J, Lodish M.

J Clin Endocrinol Metab. 2018 Aug 2. doi: 10.1210/jc.2018-00705. [Epub ahead of print]

PMID:
30113649
3.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL.

Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.

PMID:
29891538
4.

Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.

Thomas N, Glod J, Derse-Anthony C, Baple EL, Osborne N, Sturley R, Vaidya B, Newbold K, Brooke A.

Clin Endocrinol (Oxf). 2018 May;88(5):754-756. doi: 10.1111/cen.13577. Epub 2018 Mar 8. No abstract available.

PMID:
29457255
5.

Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.

Kraft IL, Akshintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, Steinberg SM, Lodish M, Waguespack SG, Kapustina O, Fox E, Balis FM, Merino MJ, Meltzer PS, Glod JW, Shern JF, Widemann BC.

Clin Cancer Res. 2018 Feb 15;24(4):753-765. doi: 10.1158/1078-0432.CCR-17-2101. Epub 2017 Nov 29.

PMID:
29187393
6.

A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC.

Cancer Chemother Pharmacol. 2017 Sep;80(3):645-652. doi: 10.1007/s00280-017-3382-x. Epub 2017 Jul 22.

PMID:
28735378
7.

Association of Plasmodium falciparum with Human Endothelial Cells in vitro.

Utter C, Serrano AE, Glod JW, Leibowitz MJ.

Yale J Biol Med. 2017 Jun 23;90(2):183-193. eCollection 2017 Jun.

8.

ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases.

Goyal N, Apolo AB, Berman ED, Bagheri MH, Levine JE, Glod JW, Kaplan RN, Machado LB, Folio LR.

J Digit Imaging. 2017 Jun;30(3):275-286. doi: 10.1007/s10278-016-9938-1.

9.

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC.

N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943.

10.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S.

Oncologist. 2016 Nov;21(11):1315-1325. doi: 10.1634/theoncologist.2016-0049. Epub 2016 Aug 26.

11.

Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.

Glod J, Rahme GJ, Kaur H, H Raabe E, Hwang EI, Israel MA.

J Pediatr Hematol Oncol. 2016 May;38(4):249-60. doi: 10.1097/MPH.0000000000000551. Review.

12.

Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer.

Glod J, Song M, Sharma A, Tyagi R, Rhodes RH, Weissmann DJ, Roychowdhury S, Khan A, Kane MP, Hirshfield K, Ganesan S, DiPaola RS, Rodriguez-Rodriguez L.

J Pers Med. 2014 Jul 15;4(3):402-11. doi: 10.3390/jpm4030402.

13.

CNS lymphoma in a patient with Shwachman Diamond syndrome.

Sharma A, Sadimin E, Drachtman R, Glod J.

Pediatr Blood Cancer. 2014 Mar;61(3):564-6. doi: 10.1002/pbc.24743. Epub 2013 Nov 8. No abstract available.

PMID:
24307640
14.

P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms.

Lin SY, Dolfi SC, Amiri S, Li J, Budak-Alpdogan T, Lee KC, Derenzo C, Banerjee D, Glod J.

Int J Oncol. 2013 Dec;43(6):1817-23. doi: 10.3892/ijo.2013.2109. Epub 2013 Sep 23.

15.

Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion.

Anton K, Banerjee D, Glod J.

PLoS One. 2012;7(4):e35036. doi: 10.1371/journal.pone.0035036. Epub 2012 Apr 4.

16.
17.

Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment.

Rattigan YI, Patel BB, Ackerstaff E, Sukenick G, Koutcher JA, Glod JW, Banerjee D.

Exp Cell Res. 2012 Feb 15;318(4):326-35. doi: 10.1016/j.yexcr.2011.11.014. Epub 2011 Dec 8.

18.

Macrophages play a key role in early blood brain barrier reformation after hypothermic brain injury.

Koneru R, Kobiler D, Lehrer S, Li J, van Rooijen N, Banerjee D, Glod J.

Neurosci Lett. 2011 Sep 1;501(3):148-51. doi: 10.1016/j.neulet.2011.06.062. Epub 2011 Jul 18.

PMID:
21782894
19.

Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu.

Rattigan Y, Hsu JM, Mishra PJ, Glod J, Banerjee D.

Exp Cell Res. 2010 Dec 10;316(20):3417-24. doi: 10.1016/j.yexcr.2010.07.002. Epub 2010 Jul 13.

PMID:
20633553
20.

Protein kinase C zeta regulates interleukin-8-mediated stromal-derived factor-1 expression and migration of human mesenchymal stromal cells.

Picinich SC, Glod JW, Banerjee D.

Exp Cell Res. 2010 Feb 15;316(4):593-602. doi: 10.1016/j.yexcr.2009.11.011. Epub 2009 Nov 24.

PMID:
19944094
22.

Mesenchymal stem cells: flip side of the coin.

Mishra PJ, Mishra PJ, Glod JW, Banerjee D.

Cancer Res. 2009 Feb 15;69(4):1255-8. doi: 10.1158/0008-5472.CAN-08-3562. Epub 2009 Feb 10. Review. Erratum in: Cancer Res. 2009 Apr 1;69(7):3240.

23.

Targeting the tumor stroma in cancer therapy.

Anton K, Glod J.

Curr Pharm Biotechnol. 2009 Feb;10(2):185-91. Review.

PMID:
19199950
24.

The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells.

Lin SY, Yang J, Everett AD, Clevenger CV, Koneru M, Mishra PJ, Kamen B, Banerjee D, Glod J.

Exp Cell Res. 2008 Oct 15;314(17):3107-17. doi: 10.1016/j.yexcr.2008.07.028. Epub 2008 Aug 8.

25.

Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells.

Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D.

Cancer Res. 2008 Jun 1;68(11):4331-9. doi: 10.1158/0008-5472.CAN-08-0943.

26.

Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model.

Wollack JB, Makori B, Ahlawat S, Koneru R, Picinich SC, Smith A, Goldman ID, Qiu A, Cole PD, Glod J, Kamen B.

J Neurochem. 2008 Mar;104(6):1494-503. Epub 2007 Dec 10.

27.

The Raz mTaz of human mesenchymal stem cells.

Banerjee D, Glod J, Rabson AB.

Stem Cells Dev. 2007 Oct;16(5):691-3. No abstract available.

PMID:
17999591
28.

Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia.

Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, Kamen BA.

Cancer Chemother Pharmacol. 2008 Jun;62(1):65-75. Epub 2007 Sep 2.

PMID:
17768625
29.

The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy.

Picinich SC, Mishra PJ, Mishra PJ, Glod J, Banerjee D.

Expert Opin Biol Ther. 2007 Jul;7(7):965-73. Review.

PMID:
17665987
30.

Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells.

Menon LG, Picinich S, Koneru R, Gao H, Lin SY, Koneru M, Mayer-Kuckuk P, Glod J, Banerjee D.

Stem Cells. 2007 Feb;25(2):520-8. Epub 2006 Oct 19.

31.

Metronomic therapy from a pharmacologist's view.

Kamen BA, Glod J, Cole PD.

J Pediatr Hematol Oncol. 2006 Jun;28(6):325-7. Review. No abstract available.

PMID:
16794497
32.

Monocytes form a vascular barrier and participate in vessel repair after brain injury.

Glod J, Kobiler D, Noel M, Koneru R, Lehrer S, Medina D, Maric D, Fine HA.

Blood. 2006 Feb 1;107(3):940-6. Epub 2005 Oct 4.

33.

What is the price of an erythrocyte and neutrophil?

Kamen BA, Glod J.

J Pediatr Hematol Oncol. 2004 Nov;26(11):699-700. No abstract available.

PMID:
15543000
34.

Preparation of floating pellets with verapamil hydrochloride.

Sawicki W, Głód J.

Acta Pol Pharm. 2004 May-Jun;61(3):185-90.

35.

Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model.

Anderson SA, Glod J, Arbab AS, Noel M, Ashari P, Fine HA, Frank JA.

Blood. 2005 Jan 1;105(1):420-5. Epub 2004 Aug 26.

36.

Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors.

Ferrari N, Glod J, Lee J, Kobiler D, Fine HA.

Gene Ther. 2003 Apr;10(8):647-56.

PMID:
12692593
37.

Pediatric glial tumors.

Cohen KJ, Broniscer A, Glod J.

Curr Treat Options Oncol. 2001 Dec;2(6):529-36. Review.

PMID:
12057098
38.

Commentary (Cohen/Glod): Current Management of Childhood Ependymoma.

Cohen KJ, Glod J.

Oncology (Williston Park). 2002 May 1;16(5). pii: 176190. No abstract available.

39.

Issues concerning the treatment of a child with a craniopharyngioma.

Glod J, Koch B, Myseros J, Breneman J, Collins MH.

Med Pediatr Oncol. 2002 May;38(5):360-7. No abstract available.

PMID:
11979463
40.

Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase.

Tokumitsu H, Brickey DA, Glod J, Hidaka H, Sikela J, Soderling TR.

J Biol Chem. 1994 Nov 18;269(46):28640-7.

41.

cDNA sequence and differential expression of the mouse Ca2+/calmodulin-dependent protein kinase IV gene.

Jones DA, Glod J, Wilson-Shaw D, Hahn WE, Sikela JM.

FEBS Lett. 1991 Sep 2;289(1):105-9.

Supplemental Content

Support Center